Central Pharmaceutical Joint Stock Company No3 (DP3) investor relations material

Executive summary

• Net revenue for Q2 2026 reached VND 128.8 billion, up from VND 94.2 billion in Q2 2025, with a six-month total of VND 263.7 billion, a 41.7% year-over-year increase.

• Profit after tax for Q2 2026 was VND 39.1 billion, up 21.7% year-over-year; six-month profit after tax totaled VND 73.9 billion, up 32% year-over-year.

• Basic EPS for Q2 2026 was VND 1,818, and for the first half of 2026 was VND 3,435, both higher than the prior year.

Financial highlights

• Gross profit margin for Q2 2026 was 36.5%, slightly down from 34.2% in Q2 2025; six-month gross profit margin was 32.9%.

• Financial income for the first half of 2026 was VND 18.4 billion, up from VND 10.5 billion year-over-year, mainly from interest income.

• Operating profit for Q2 2026 was VND 48.6 billion, up 18.2% year-over-year.

• Total assets as of June 30, 2026, were VND 767.0 billion, up from VND 756.1 billion at the start of the year.

• Cash and cash equivalents increased to VND 6.6 billion from VND 4.5 billion at the start of the year.

Outlook and guidance

• No explicit forward-looking guidance provided, but strong revenue and profit growth in H1 2026 indicate positive momentum.